Canaccord analyst John Newman lowered the firm’s price target on Atreca to $8 from $20 and keeps a Buy rating on the shares. The analyst said his lower price target reflects decreased total market assumptions, as we believe the combination arm versus monotherapy arm may be the best opportunity for ATRC-101.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on BCEL:
- Atreca downgraded to In Line from Outperform at Evercore ISI
- Atreca: Phase 2 go/no-go decisions for ATRC-101 expected by end-of-year
- Atreca reports Q4 EPS (55c), consensus (59c)
- Atreca Reports Fourth Quarter and Full-Year 2022 Financial Results and ATRC-101 Data Update
- Atreca (BCEL) Q4 Earnings Cheat Sheet